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Background: The antiproliferative activity of octreotide LAR in neuroendocrine tumours (NETs) has been demonstrated by small
retrospective studies and confirmed by a prospective phase III trial (PROMID). However, there are limited data about the duration
and predictors of response. The aim of our retrospective study was to determine the time to radiological progression (TTRP) of
disease and the factors that were associated with better response.
Methods: A total of 254 treatment naı¨ve patients with advanced NETs and positive somatostatin receptor scintigraphy were
included. Mean follow-up period was 42 months.
Results: The location of primary was in the small bowel in 204, pancreas in 22, lungs in 14, rectum in 7 and unknown in 7 patients.
Most tumours were well-differentiated, G1 (58%) and G2 (23%). The majority of patients commenced octreotide LAR due to
functional symptoms (57%), radiological progression (10%) or in the presence of asymptomatic and stable disease on the basis of
data from the PROMID trial (18.5%). Partial response occurred in 5%. For all patients, the median TTRP was 37 months (95%
confidence interval, CI: 32–52 months). There was a statistically significant shorter TTRP in patients with pancreatic tumours, liver
metastases and intermediate grade tumours. Extremely raised (410 times the upper limit of normal) baseline chromogranin
A levels were associated with an unfavourable outcome. In contrast, male sex, carcinoid heart disease and initiation of treatment in
the presence of stable disease were predictive of a better response. Age, extra-hepatic metastases, presence of mesenteric
desmoplasia, previous resection and functional status of the primary tumour did not affect response.
Conclusions: The duration of the antiproliferative effect of octreotide LAR seems to be longer than previously reported. This study
has identified several predictors of response in a large cohort of patients with NETs on somatostatin analogue therapy.
Neuroendocrine tumours (NETs) are rare neoplasms with an
incidence between 2 and 9.3 per 100 000 persons per year (Ramage
et al, 2012). They represent a heterogeneous group of neoplasms,
arising from neuroendocrine cells derived from the diffuse
endocrine system. They may be associated with a specific
syndrome due to hormone hypersecretion, which differentiates
‘functional’ from ‘non-functional’ tumours.
Somatostatin analogues (SSA) are commonly used to treat
symptoms associated with hormone hypersecretion and have a
favourable safety profile. The antiproliferative activity of SSA in
NETs has been recently confirmed in two randomised placebo-
controlled trials (Rinke et al, 2009; Toumpanakis and Caplin, 2013;
Caplin et al, 2014). The PROMID trial was a placebo-controlled,
double-blind, randomised study assessing the effect of octreotide
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LAR on the control of tumour growth in patients with metastatic,
well-differentiated midgut NETs. The study demonstrated that
octreotide LAR significantly lengthened the time to tumour
progression compared with placebo (median time to tumour
progression 14.3 months vs 6 months, respectively; Rinke et al,
2009). More recently, another randomised, double-blind, placebo-
controlled trial evaluated the effect of lanreotide in patients with
metastatic, well- or moderately differentiated, non-functional
enteropancreatic NETs (the CLARINET trial). This study showed
that lanreotide was associated with a significantly prolonged
progression-free survival compared with placebo (median progres-
sion-free survival not reached vs 18 months, respectively; Caplin
et al, 2014).
However, there are limited data regarding the duration of response
and factors predictive of tumour control in patients with NETs on
SSA therapy. The aims of the present study were to determine the
mean time to radiological progression (TTRP) of disease and factors
affecting radiological response to SSA therapy in a large cohort of
patients with NETs treated with octreotide LAR.
MATERIALS AND METHODS
Patients. A total of 254 patients with NETs treated with octreotide
LAR (as monotherapy) in our centre from 2001 to 2014, were
included in this retrospective study. All patients had confirmed
histopathological diagnosis. All patients were treatment-naı¨ve, but
primary tumour resection before somatostatin analogue therapy
was not an exclusion criterion. In addition, all patients had a
positive somatostatin receptor scintigraphy before commencement
of octreotide LAR.
Somatostatin analogue therapy. All patients (who were soma-
tostatin naı¨ve) had an initial test dose of subcutaneous (s.c.)
octreotide (50 mg). If no immediate adverse effect was noted,
patients either had an initial 2-week course of s.c. octreotide (100/
200 mg tds) and then were switched over to octreotide LAR or
patients were given monthly octreotide LAR after no reaction to a
single test dose of s.c. octreotide. The initial dose of octreotide
LAR was 20mg/28 days in 198 patients and 30mg/28 days in
56 patients.
Study design. A retrospective review of patient electronic records
was performed. Data collected included patient demographics
(age, sex), data on the characteristics of treatment with octreotide
LAR (dose, indication), tumour characteristics (location of
primary, functional status, grade, presence of carcinoid heart
disease and mesenteric desmoplasia, presence of liver or extra-
hepatic metastases, extent of liver involvement, resection of
primary and TTRP), and biochemical data (baseline serum
chromogranin A (CgA)).
NET tumours were retrospectively classified and graded
according to WHO 2010 (Bosman et al, 2010). Tumours were
graded into three levels based on tumour cell proliferation: G1:
mitotic counto2 per 10 high-power fields and/or Ki67p2%; G2:
mitotic count 2–20 per 10 high-power fields and/or Ki67 3–20%;
G3: mitotic count420 per 10 high-power fields and/or Ki67X20%
(Rindi et al, 2007).
Extent of liver involvement (0: absence of liver metastases,
1: volume of liver metastases affecting o25% of hepatic
parenchyma, 2: volume of liver metastases affecting 25–50% of
hepatic parenchyma, 3: volume of liver metastases affecting450%
of hepatic parenchyma) was evaluated by one experienced
radiologist (L.G.). The presence of mesenteric desmoplasia was
assessed by computed tomography imaging. However, assessment
of the extent or degree of desmoplastic reaction was not performed
due to the absence of established classification systems.
The aims of this retrospective study were to demonstrate the
mean TTRP, as well as identify factors affecting the antiprolifera-
tive activity of octreotide LAR in a large cohort of patients with
NETs.
Radiological assessment was based on cross-sectional imaging in
4–6 month intervals, using the revised RECIST (version 1.1)
criteria (Eisenhauer et al, 2009). Many variables were assessed as
potential predictive factors of response to treatment with octreotide
LAR: age, sex, treatment indication, location of primary tumour,
extent of liver involvement, extra-hepatic metastases (bone,
peritoneum, mesentery), presence of carcinoid heart disease
and mesenteric desmoplasia, tumour grade, functional status
(functional or non-functional), resection of primary tumour and
baseline CgA level.
Statistical analysis. Non-parametric Kaplan–Meier techniques
were used to evaluate times to radiological progression, including
the median and associated 95% CI, in strata defined by the various
explanatory variables. A semi-parametric Cox regression model
was used to perform multivariate analysis on a sample of 152
patients with complete information on all covariates of interest
(Collett, 2003). By including fewer covariates, additional multi-
variate models were fitted to larger patient samples to test the
robustness of the findings to potential sample bias.
RESULTS
Patient characteristics. A total of 254 patients were included in
this retrospective study. The patients’ mean age was 60.5±12.8
years. The male to female ratio was 1.1 : 1. The location of the
primary tumour was in the small bowel in 204 (80%), pancreas in
22 (8.5%), lung in 14 (5.5%), rectum in 7 (2.5%) and unknown in 7
patients (2.5%). The histological grade was G1 in 148 (58%), G2 in
59 (23%), G3 in 1 (0.5%) and not available in 47 patients (18.5%).
The study population included 183 patients with functional
tumours (72%) (of which 97% were serotonin secreting, 1%
glucagonomas, 1.5% gastrinomas and 0.5% insulinomas), 67 with
non-functional tumours (26%), whereas data on functional status
were not available in 4 patients (2%). The primary tumour had
been resected before commencement of octreotide LAR in 117
(46%) patients. Indications for commencement of octreotide LAR
included functional symptoms in 57%, radiological progression in
10%, a combination of functional symptoms and radiological
progression in 3%, whereas 18.5% of patients were asymptomatic
with stable disease and started treatment on the basis of data from
the PROMID trial (CLARINET trial data were not available during
the period covered in this retrospective cohort study). The duration
of stable disease before initiation of SSA therapy in this group of
patients was at least 3 months. A total of 8% of patients were
commenced on octreotide LAR due to a combination of functional
symptoms and stable disease (on the basis of data from the
PROMID trial) and the indication was not clearly recorded in 3.5%
of cases.
A summary of patient baseline characteristics is provided in
Table 1.
Partial (objective) response, TTRP and univariate analysis of
predictive factors of tumour control during treatment with
octreotide LAR. Partial (objective) response was noted in 13
patients (5%). For all patients the median and mean TTRP were 37
months (95% CI: 32–52 months) and 51 months (95% CI: 45–57
months), respectively (Figure 1).
The univariate analysis demonstrated that liver and skeletal
metastases, G2 tumours and baseline serum CgA levels more than
10 times the upper limit of normal were predictive factors of a
shorter TTRP, whereas male sex was associated with a statistically
significantly longer TTRP.
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Pancreatic and rectal primary tumours demonstrated a trend
towards shorter TTRP and tumours associated with carcinoid heart
disease demonstrated a trend towards longer TTRP, but both
associations did not reach the level of statistical significance.
In contrast, age, treatment indication, peritoneal or mesenteric
metastases, functional status, presence of mesenteric desmoplasia
and resection of primary tumour were not found to be predictive
factors affecting response to treatment.
The results of the univariate analysis are shown in Table 2.
Multivariate analysis of predictive factors of tumour control
during treatment with octreotide LAR. The multivariate analysis
demonstrated that G2 tumours, liver metastases and pancreatic
primary tumours were predictors of a shorter TTRP. In contrast,
male sex and presence of carcinoid heart disease were predictors of
a longer TTRP. In addition, initiation of treatment in asympto-
matic patients with stable disease was predictive of a better
response to octreotide LAR.
Age, presence of skeletal, peritoneal and mesenteric metastases,
functional status, tumour resection and presence of mesenteric
desmoplasia were not found to be predictive of tumour response to
therapy.
The results of the multivariate analysis are shown in Table 3.
Two additional multivariate analysis models including fewer co-
variates were fitted to larger patient samples with complete data, in
order to assess the validity of these findings given the potential risk
of sampling bias (Supplementary Tables 1 and 2).
TTRP stratified by factors predictive of response to treatment
with octreotide LAR. The following factors were identified by
multivariate analysis as predictive of a favourable or unfavourable
response to treatment with octreotide LAR and the TTRP stratified
by each of these factors was calculated separately:
Tumour grade. The median TTRP was 45 months (95% CI: 33–72
months) for patients with G1 tumours and 21 months (95% CI:
15–37 months) for patients with G2 tumours (Figure 2).
Liver involvement. The median TTRP was 105 months (95% CI:
36, NA) for patients without liver metastases, 37 months (95% CI:
26–79 months) for patients with volume of liver metastaseso25%,
23 months (95% CI: 13, NA) for patients with volume of liver
metastases 25–50% and 33 months (95% CI: 20, NA) for patients
with volume of liver metastases 450% (Figure 2).
Location of primary tumour. The median TTRP was 20 months
(95% CI: 12–79 months) for patients with a pancreatic primary
tumour, 43 months (95% CI: 32–64 months) for patients with a
small bowel primary, 4 months (95% CI: 11, NA) for patients with
a lung primary and 8 months (95% CI: 4, NA) for those with a
rectal primary (Figure 2).
Treatment indication. The median TTRP was 53 months
(95% CI: 28, NA) for asymptomatic patients with stable disease.
The median TTRP was 32 months (95% CI: 27–51 months) for
patients whose indication was functional symptoms and 50 months
(95% CI: 35, NA) for patients whose indication was radiological
progression. The median TTRP was 43 months (95% CI: 21, NA)
for patients with a combination of functional symptoms and
radiological progression and 20 months (95% CI: 19, NA) for
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Figure 1. Kaplan–Meier estimate of the survival function for the time
to tumour progression for all 254 patients. The crosses indicate right-
censored data whereby patients’ tumours were stable at the last time of
contact before being lost to follow-up. The median time to tumour
progression is 37 months (95% CI: 32–52 months), given by the time at
which the Kaplan–Meier estimate of the survival function is 0.5. The
mean time to tumour progression is 51 months (95% CI: 45–57 months),
calculated using a restricted upper time limit of 120 months.
Table 1. Patient baseline characteristics
N¼254
Sex
Male 134
Female 120
Indication for treatment
Functional symptoms 145
Functional symptomsþprogression 8
Functional symptomsþPROMID data 21
Progression 24
PROMID data 47
Unknown 9
Location of primary
Lung 14
Pancreas 22
Rectum 7
Small bowel 204
Unknown 7
Grade
Low 148
Intermediate 59
High 1
Unknown 47
Functional status
Functional 183
Non-functional 67
Unknown 4
Carcinoid heart disease
Yes 24
No 229
Unknown 1
Desmoplasia
Yes 67
No 185
Unknown 2
Chromogranin A
Normal 29
Up to 10 times higher than upper limit of normal 98
410 times higher than upper limit of normal 35
Unknown 92
Primary tumour resection
Yes 117
No 134
Unknown 3
Abbreviation: PROMID¼prospective phase III trial.
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patients, whose indications were both functional symptoms and
stable disease (initiated on SSA therapy on the basis of evidence
from the PROMID trial; Figure 2).
Carcinoid heart disease. The median TTRP was 36 months
(95% CI: 30–51 months) for patients without carcinoid heart
disease and 72 months (95% CI: 33, NA) for patients with
carcinoid heart disease (Figure 2).
A subsequent analysis of electronic records of patients with
carcinoid heart disease revealed that the majority of patients had
mild carcinoid heart disease with NYHA class I (54%) or II
(37.5%). Most of these patients (92%) also had N-terminal pro
b-type natriuretic peptide (NT pro-BNP) values ofo400 pgml 1,
which has been proposed as a cut-off value predictive of a
diagnosis of chronic heart failure (Al-Mohammad et al, 2010).
Sex. The median TTRP was 32 months (95% CI: 23–45 months)
for female and 49 months (95% CI: 36–96 months) for male
patients (Figure 2).
DISCUSSION
Partial (objective) response and TTRP. The present study
demonstrated that in a large cohort of patients with NETs on
octreotide LAR the partial (objective) response rate was 5%. This is in
keeping with the results of other prospective and retrospective studies,
which have shown partial (objective) response rates of 0–10%
(Saltz et al, 1993; Arnold et al, 1996; di Bartolomeo et al, 1996;
Eriksson et al, 1997; Wymenga et al, 1999; Ducreux et al, 2000;
Aparicio et al, 2001; Shojamanesh et al, 2002; Faiss et al, 2003; Rinke
et al, 2009; Toumpanakis et al, 2009; Martı´n-Richard et al, 2013;
Palazzo et al, 2013; Ramundo et al, 2014; Supplementary Table 3).
However, in our study the TTRP was 37 months, which is
longer than that reported in most other studies (Arnold et al, 1996;
Shojamanesh et al, 2002; Butturini et al, 2006; Rinke et al, 2009;
Toumpanakis et al, 2009; Palazzo et al, 2013; Martı´n-Richard et al,
2013; Caplin et al, 2014; Supplementary Table 3). It is possible that
differences in the baseline patient and tumour characteristics
among various studies may account for this variation in TTRP.
Table 2. Descriptive univariate analysis of explanatory factors predicting time to tumour progression for patients treated with
octreotide
Cox regression
Explanatory factor Levels Sample size
Progression
events
KM median months to
progression (95% CI) Coefficient P-values
Age p60 115 64 43 (32, 71) NA NA
460 139 66 33 (28, 65) 0.04 0.84
Sex Female 120 72 32 (23, 45) NA NA
Male 134 58 49 (36, 96) 0.42 0.02
Reason for treatment Functional 145 83 32 (27, 51) NA NA
Functional & progression 8 4 43 (21, NA) 0.23 0.65
Functional & PROMID 21 10 30 (19, NA) 0.17 0.62
Progression 24 11 50 (35, NA) 0.56 0.10
PROMID 47 17 53 (28, NA) 0.25 0.35
Primary tumour Small bowel 204 101 43 (32, 64) NA NA
Pancreas 22 17 20 (12, 79) 0.52 0.058
Lung 14 6 NA (11, NA) 0.37 0.38
Rectum 7 4 8 (4, NA) 1.4 0.062
Volume liver metastases 0 51 16 105 (36, NA) NA NA
1 79 39 37 (26, 79) 0.63 0.036
2 37 20 23 (13, NA) 0.88 0.0089
3 26 15 33 (20, NA) 0.87 0.016
Skeletal metastases No 221 110 40 (33, 60) NA NA
Yes 32 19 20 (16, NA) 0.51 0.043
Peritoneal metastases No 176 87 46 (30, 71) NA NA
Yes 78 43 33 (30, 45) 0.28 0.14
Mesenteric metastases No 209 109 37 (31, 64) NA NA
Yes 43 19 32 (22, NA) 0.043 0.86
Carcinoid heart No 229 119 36 (30, 51) NA NA
Yes 24 10 72 (33, NA) 0.58 0.082
Grade 1 (low) 148 71 45 (33, 72) NA NA
2 (intermediate) 59 37 21 (15, 37) 0.73 o0.001
Functional No 183 92 45 (31, 65) NA NA
Yes 67 34 36 (26, NA) 0.027 0.89
Desmoplasia No 185 96 36 (30, 64) NA NA
Yes 67 32 36 (30, NA) 0.14 0.5
Tumour resected No 134 72 36 (30, NA) NA NA
Yes 117 55 43 (30, 78) 0.17 0.36
Chromogranin A o60 (normal) 29 10 93 (35, NA) NA NA
61–600 (elevated) 98 42 53 (19, 79) 0.59 0.097
4600 (very elevated) 35 22 30 (19, NA) 1.15 0.0029
Abbreviations: CI¼ confidence interval; KM¼Kaplan–Meier; NA¼not available. For the Cox regression results: (a) coefficients are negative for a slower time to tumour progression (a better response)
and vice versa, and (b) baseline factor levels are not associated with a coefficient or P-value and are denoted NA. Some upper confidence limits for the KM estimate of the median time to progression
could not be estimated from the available data and are denoted NA. The median time to progression of bronchial primary tumours could also not be estimated from the available data.
BRITISH JOURNAL OF CANCER Antiproliferative activity of octreotide LAR
1324 www.bjcancer.com |DOI:10.1038/bjc.2016.349
Predictive factors of tumour response. There is only a small
number of studies that have identified predictors of tumour
response to SSA therapy and these are summarised in
Supplementary Table 4.
Our study is the largest retrospective study in the literature
aiming to determine predictive factors of radiological response to
SSA therapy. Its large sample size has allowed the analysis of
multiple variables as potential predictive factors. Such analysis
was not feasible in previous studies due to the small study
samples. Some of our study findings are in keeping with those of
previously published studies, although some differences are also
present.
In our study, the multivariate analysis revealed that G2 tumours
were less likely to respond to octreotide LAR. Similarly, a small
prospective study demonstrated that lower proliferation index
(Ki67) predicted superior tumour growth control, although this
association did not quite reach the level of statistical significance,
perhaps due to the small sample size (Martı´n-Richard et al, 2013).
Another small prospective study which included advanced, well-
differentiated, non-functional pancreatic NETs concluded that
tumour progression correlated with a Ki67X5%, weight loss and
absence of abdominal pain (Butturini et al, 2006).
Our study also showed that liver metastases are predictive of a
poor response to treatment. Palazzo et al (2013) also found that
Ki67o5%, hepatic tumour loado25% and pre-treatment stability
were associated with disease stability on lanreotide therapy. The
PROMID trial also suggested that the antiproliferative activity of
octreotide LAR was more pronounced in patients with a low
(p10%) hepatic tumour load and a resected primary tumour
(Rinke et al, 2009). A previous retrospective study performed in
our centre showed that in a subgroup of patients with G1 tumours,
bilobar liver metastases at the time of commencement of treatment
and plasma CgA levels41000 pmol l 1 were predictive of
radiological progression (Toumpanakis et al, 2009). Interestingly,
our univariate analysis also showed that CgA levels410 times the
upper limit of normal were predictive of a poor response, although
this could not be confirmed in the multivariate analysis due to
missing data in a large number of subjects.
In addition, our multivariate analysis showed that pancreatic
tumours were less likely to respond to treatment. A previous
prospective study also demonstrated that patients with midgut
NETs showed a statistically significant prolonged length of time to
tumour progression compared with foregut tumours (most of
which were pancreatic), although the study population included
not only patients treated with lanreotide, but also patients treated
with interferon or a combination of both drugs (Faiss et al, 2003).
Moreover, our results demonstrated that asymptomatic patients
with stable disease were more likely to respond to treatment.
Similarly, other studies have shown that rapidly progressive
tumours are less likely to respond to treatment compared with
stable or slowly progressive tumours before initiation of SSA
(Aparicio et al, 2001; Shojamanesh et al, 2002; Palazzo et al, 2013).
The present study also revealed that male sex and carcinoid
heart disease were favourable predictive factors of tumour
response. These variables were statistically significant across all
multivariate analysis models. This was an unexpected finding, as
carcinoid heart disease is associated with poor prognosis. However,
an analysis of the electronic case notes of patients with carcinoid
heart disease revealed that the vast majority of cases had only mild
disease and it is possible that they were perhaps followed-up and
treated more aggressively, which resulted in a more favourable
outcome.
Finally, primary tumour resection has been identified in other
studies as predictive of a better response to SSA therapy (Panzuto
et al, 2006). In our study, this factor was not found to be significant
in any of the multivariate analysis models.
Although many of our study findings are in keeping with those
of other studies, some differences are also present. These may be
due to differences in predictive factors assessed, heterogeneity of
study populations, differences in sample sizes and use of different
SSAs amongst various studies. In practical terms, however,
decisions regarding initiation of SSA therapy still need to be made
on a case-by-case basis, although these may be influenced by the
presence of associated predictive factors.
Limitations and conclusions. There are several limitations to this
study. Because of retrospective data collection the results are
potentially subject to interpretation bias and bias because
of missing data. In addition, this is a single-centre cohort study
in a tertiary and quaternary referral centre which attracts many
referrals outside its geographical catchment area. Therefore,
the profile of our patients and clinical practices may not be
typical of regional centres and the extrapolation of our findings
to other populations can be questioned. It is difficult to quantify
the degree of potential bias, but the fact that many of our results
are in keeping with those of previous studies suggests that
this may not be a major area of concern. Furthermore, in our
Table 3. Coefficients, s.e. and P-values for the maximum Cox
regression (proportional hazards) model
Explanatory factor Levels Coefficient s.e. P-values
Age p60 NA NA NA
460 0.33 1.4 0.26
Sex Female NA NA NA
Male 0.46 0.27 0.010
Skeletal metastases No NA NA NA
Yes 0.027 0.43 0.95
Peritoneal metastases No NA NA NA
Yes 0.38 0.32 0.24
Mesenteric No NA NA NA
metastases Yes 0.22 0.36 0.54
Carcinoid heart
disease
No NA NA NA
Yes 1.5 0.63 0.019*
Functional No NA NA NA
Yes 0.0011 0.33 0.99
Desmoplasia No NA NA NA
Yes 0.022 0.33 0.95
Tumour resected No NA NA NA
Yes 0.057 0.28 0.84
Treatment indication Functional NA NA NA
Functional and
progression
1.87 1.2 0.11
Functional and
PROMID
0.29 0.43 0.51
Progression 0.99 0.51 0.051
PROMID 1.0 0.36 0.011*
Primary tumour Small bowel NA NA NA
Pancreas 1.4 0.41 0.001**
Lung 1.5 1.0 0.15
Rectum 0.88 1.1 0.43
Volume of liver 0 NA NA NA
metastases 1 1.1 0.41 0.006**
2 1.2 0.47 0.013*
3 1.2 0.49 0.016*
Tumour grade Low NA NA NA
Intermediate 1.0 0.29 0.001*
High NA NA NA
Abbreviations: NA¼ not available; PROMID¼prospective phase III trial. Coefficients are
negative for a slower time to tumour progression (a better response) and vice versa.
Baseline factor levels are not associated with a coefficient or P-value and are denoted NA.
Sample size is 152 (254 total). Likelihood-ratio statistic¼ 55 on 21 degrees of freedom
(comparing with the null intercept-only model), Po0.001. *Po0.05; **Po0.01.
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study the vast majority of patients had small bowel primary
tumours (n¼ 204) followed by pancreatic (n¼ 22), lung (n¼ 14)
and rectal primaries (n¼ 7). Therefore, our results may be
more reliable for patients with small bowel and pancreatic
NETs and less robust for other NETs. Finally, the majority of
patients with functional tumours were those with carcinoid syndrome
as a result of a small bowel primary NET. Only a minority of patients
had functional pancreatic tumours, such as insulinoma or glucago-
noma. As a result, our findings on the impact of functional status on
the antiproliferative activity of SSA therapy mainly reflect the presence
or not of carcinoid syndrome.
In conclusion, the current study suggests that the duration of
the anti-proliferative effect of octreotide LAR is longer than
previously reported. Male sex, carcinoid heart disease and possibly
disease stability at the time of commencement of SSA therapy are
predictive of a better response, although the vast majority of
patients had minor cardiac disturbance and might have been
treated and followed-up more aggressively resulting in a more
positive outcome. Age, extra-hepatic metastases (other than
perhaps skeletal), mesenteric desmoplasia, tumour functional
status and primary tumour resection do not appear to have any
effect on treatment. In contrast, liver (and perhaps skeletal)
metastases, intermediate grade tumours, pancreatic primary
tumours and possibly extremely raised CgA levels may be
associated with an unfavourable response.
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